HLA等位基因限制性免疫介导的药物不良反应:遗传预测框架。

IF 11.2 1区医学 Q1 PHARMACOLOGY & PHARMACY

Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-13 DOI:10.1146/annurev-pharmtox-052120-014115

Kanoot Jaruthamsophon, Paul J Thomson, Chonlaphat Sukasem, Dean J Naisbitt, Munir Pirmohamed

{"title":"HLA等位基因限制性免疫介导的药物不良反应:遗传预测框架。","authors":"Kanoot Jaruthamsophon, Paul J Thomson, Chonlaphat Sukasem, Dean J Naisbitt, Munir Pirmohamed","doi":"10.1146/annurev-pharmtox-052120-014115","DOIUrl":null,"url":null,"abstract":"Human leukocyte antigen (HLA) is a hallmark genetic marker for the prediction of certain immune-mediated adverse drug reactions (ADRs). Numerous basic and clinical research studies have provided the evidence base to push forward the clinical implementation of HLA testing for the prevention of such ADRs in susceptible patients. This review explores current translational progress in using HLA as a key susceptibility factor for immune ADRs and highlights gaps in our knowledge. Furthermore, relevant findings of HLA-mediated drug-specific T cell activation are covered, focusing on cellular approaches to link genetic associations to drug-HLA binding as a complementary approach to understand disease pathogenesis.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":11.2000,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":"{\"title\":\"HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction.\",\"authors\":\"Kanoot Jaruthamsophon, Paul J Thomson, Chonlaphat Sukasem, Dean J Naisbitt, Munir Pirmohamed\",\"doi\":\"10.1146/annurev-pharmtox-052120-014115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Human leukocyte antigen (HLA) is a hallmark genetic marker for the prediction of certain immune-mediated adverse drug reactions (ADRs). Numerous basic and clinical research studies have provided the evidence base to push forward the clinical implementation of HLA testing for the prevention of such ADRs in susceptible patients. This review explores current translational progress in using HLA as a key susceptibility factor for immune ADRs and highlights gaps in our knowledge. Furthermore, relevant findings of HLA-mediated drug-specific T cell activation are covered, focusing on cellular approaches to link genetic associations to drug-HLA binding as a complementary approach to understand disease pathogenesis.\",\"PeriodicalId\":8057,\"journal\":{\"name\":\"Annual review of pharmacology and toxicology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":11.2000,\"publicationDate\":\"2022-01-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual review of pharmacology and toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1146/annurev-pharmtox-052120-014115\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/9/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of pharmacology and toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-pharmtox-052120-014115","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 7

摘要

人类白细胞抗原(HLA)是预测某些免疫介导的药物不良反应(adr)的标志性遗传标记。大量的基础和临床研究为推进HLA检测在易感患者中预防此类不良反应的临床实施提供了证据基础。本文综述了利用HLA作为免疫不良反应的关键易感因子的目前翻译进展，并强调了我们在这方面的知识差距。此外，还涵盖了hla介导的药物特异性T细胞活化的相关发现，重点介绍了将遗传关联与药物- hla结合联系起来的细胞方法，作为了解疾病发病机制的补充方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction.

Human leukocyte antigen (HLA) is a hallmark genetic marker for the prediction of certain immune-mediated adverse drug reactions (ADRs). Numerous basic and clinical research studies have provided the evidence base to push forward the clinical implementation of HLA testing for the prevention of such ADRs in susceptible patients. This review explores current translational progress in using HLA as a key susceptibility factor for immune ADRs and highlights gaps in our knowledge. Furthermore, relevant findings of HLA-mediated drug-specific T cell activation are covered, focusing on cellular approaches to link genetic associations to drug-HLA binding as a complementary approach to understand disease pathogenesis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annual review of pharmacology and toxicology 医学-毒理学

CiteScore

27.80

自引率

0.00%

发文量

期刊介绍： Since 1961, the Annual Review of Pharmacology and Toxicology has been a comprehensive resource covering significant developments in pharmacology and toxicology. The journal encompasses various aspects, including receptors, transporters, enzymes, chemical agents, drug development science, and systems like the immune, nervous, gastrointestinal, cardiovascular, endocrine, and pulmonary systems. Special topics are also featured in this annual review.